Cyfuse Biomedical K.K. (TYO:4892)

Japan flag Japan · Delayed Price · Currency is JPY
621.00
-19.00 (-2.97%)
Mar 9, 2026, 3:30 PM JST
-44.65%
Market Cap 6.19B
Revenue (ttm) 230.00M
Net Income (ttm) -763.00M
Shares Out 9.96M
EPS (ttm) -86.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 52,900
Average Volume 77,005
Open 610.00
Previous Close 640.00
Day's Range 603.00 - 626.00
52-Week Range 516.00 - 1,227.00
Beta 1.53
RSI 45.93
Earnings Date Feb 13, 2026

About Cyfuse Biomedical K.K.

Cyfuse Biomedical K.K. engages in the development, manufacture, and sale of regenerative medicine-related products in Japan and the United States. The company develops cellular products for the regenerative medicine and cellular therapy fields; and undertakes various contracts for research cell products. It also offers Bio 3D Printer for use in the regeneration of various tissues and organs, such as cartilage and bones, blood vessels, and nerves; regenova, a bio 3D printer for 3D stacking of cells; and S-PIKE that develops 3D-structures from ce... [Read more]

Sector Healthcare
Founded 2010
Employees 21
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4892
Full Company Profile

Financial Performance

In 2025, Cyfuse Biomedical K.K.'s revenue was 230.00 million, an increase of 325.93% compared to the previous year's 54.00 million. Losses were -763.00 million, -12.50% less than in 2024.

Financial Statements

News

There is no news available yet.